Thioguanosine

Thioguanosine

SCHEMBL4083505

Nc1nc(S)c2ncn(C3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.73
SLC29A1 Q99808 7/20 0.72
ADORA3 P0DMS8 2/20 0.72
ADORA1 P30542 2/20 0.72
PGK1 P00558 1/20 0.69
PGK2 P07205 1/20 0.69
LMNA P02545 1/20 0.66
NT5E P21589 1/20 0.66
HIF1A Q16665 1/20 0.66
ADORA2A P29274 2/20 0.65
ADORA2B P29275 2/20 0.65
DPP4 P27487 1/20 0.63
MEN1 O00255 1/20 0.63
SLC28A1 O00337 1/20 0.63
MAP3K7 O43318 1/20 0.63
SLC28A2 O43868 1/20 0.63
GAPDH P04406 1/20 0.63
MAPK1 P28482 1/20 0.63
STAT6 P42226 1/20 0.63
PI4KA P42356 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thioguanosine SCHEMBL608145 1.00 CYP2C19 (0.73) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL23927999 1.00 CYP2C19 (0.73) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL6748957 1.00 CYP2C19 (0.73) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL8185769 1.00 CYP2C19 (0.73) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL8612570 0.99 CYP2C19 (0.72) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL8612560 0.99 CYP2C19 (0.72) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL3861782 0.94 CYP2C19 (0.67) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL3294897 0.94 CYP2C19 (0.67) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL11084568 0.93 CYP2C19 (0.69) CYP2C19SLC29A1ADORA3ADORA1PGK1
Thioguanosine SCHEMBL3928265 0.91 CYP2C19 (0.62) CYP2C19SLC29A1ADORA3ADORA1PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355472-B2 ACID PHOSPHATASE AJINOMOTO CO., INC. (JP) 2002-03-12 US claimed
US-20020004590-A1 Method for producing nucleoside-5'-phosphate ester MIHARA YASUHIRO (JP) 2002-01-10 US claimed
US-6207435-B1 MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES AJINOMOTO CO., INC. (JP) 2001-03-27 US claimed
US-6015697-A ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY AJINOMOTO CO., INC. (JP) 2000-01-18 US claimed
WO-2019195494-A1 COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-10-10 WO disclosed
US-7575901-B2 Propagating escherichia mutant which produces 5'-inosinic acid or 5'-guanylic acid; identifying nucleotidase gene associated with generating nucleoside 5'-phosphate esters AJINOMOTO CO., INC. (JP) 2009-08-18 US disclosed
EP-1392639-B1 PYRUVATE DERIVATIVES GALILEO LAB INC (US) 2008-09-17 EP disclosed
US-7385051-B2 Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof BAR-LLAN UNIVERSITY (IL) 2008-06-10 US disclosed
US-20080026428-A1 METHOD FOR PRODUCING NUCLEOTIDE BY FERMENTATION AJINOMOTO CO., INC. (JP) 2008-01-31 US disclosed
EP-0832970-B1 PROCESS FOR PRODUCING NUCLEOSIDE-5'-PHOSPHATE ESTER AJINOMOTO KK (JP) 2007-01-17 EP disclosed
EP-1170370-B1 Method for producing nucleotide by fermentation AJINOMOTO KK (JP) 2006-09-27 EP disclosed
US-20060166248-A1 Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof BAR-ILAN UNIVERSITY (IL) 2006-07-27 US disclosed
US-20020098494-A1 Method for producing nucleotide by fermentation AJINOMOTO CO., INC. (JP) 2002-07-25 US disclosed
US-6355472-B2 ACID PHOSPHATASE AJINOMOTO CO., INC. (JP) 2002-03-12 US disclosed
EP-1170370-A2 Method for producing nucleotide by fermentation Ajinomoto Co., Inc. (JP) 2002-01-09 EP disclosed
US-6207435-B1 MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES AJINOMOTO CO., INC. (JP) 2001-03-27 US disclosed
US-6015697-A ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY AJINOMOTO CO., INC. (JP) 2000-01-18 US disclosed
US-6010851-A ALLOWING AN ACID PHOSPHATASE HAVING A LOWERED PHOSPHOMONOESTERASE ACTIVITY TO ACT UNDER A CONDITION OF PH 3.0 TO 5.5 ON A NUCLEOSIDE AND A PHOSPHATE GROUP DONOR AJINOMOTO CO., INC. (JP) 2000-01-04 US disclosed
EP-0857788-A2 Method for producing nucleoside-5'-phosphate ester Ajinomoto Co., Inc. (JP) 1998-08-12 EP disclosed
EP-0832970-A1 PROCESS FOR PRODUCING NUCLEOSIDE-5'-PHOSPHATE Ajinomoto Co., Inc. (JP) 1998-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166248-A1 Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof NUDT1, NT5C2, DUT CYP2C19 4370/4885SLC29A1 118/4885ADORA3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.